Contents:
Document Title
Clinical Guideline for the Management of Patients with Parkinson’s disease who are approaching the end of life
Document Date
July 2024
Document Purpose and Intended Audience
This guideline is intended to provide specific recommendations for symptom and medication management for patients with Parkinson’s disease in the last days or weeks of life, whether in primary or secondary care.
Author
Authors: Dr Lawrence Greensall and Dr Hannah Currie
Review and Contributions:
Dr Asim Majeed – Consultant Geriatrician
Alison Fletcher and Rose Crouch – Parkinson’s Clinical Nurse Specialists
Dr Rebecca Dawber, Dr Mariam George and Dr Anna Lock – Palliative Care Consultants
Dr Sam Niaz – Palliative Care Registrar
Dr Rosanna Montgomery – Specialty Doctor in Palliative care
Dr Rebecca Edwards – Stroke Registrar and Specialty Doctor in Palliative Care
Consultation Process
Adapted from Guidance in use at Sandwell and West Birmingham NHS Trust
Monitoring
This will be audited and reviewed every 3 years
Review Date
(must be within three years)
July 2027
Approval Signatures:
SPAGG chair
Dr Jon Tomas
SPAGG secretary
Dr Alice Gray
Date Approved by SPAGG: July 2024
Date submitted to Area Prescribing Committee: N/A
Version History
Version 1
Date
July 2024
Summary of change/ process
Endorsed and approved by SPAGG
Disclaimer
These Guidelines are intended for use by healthcare professionals and the expectation is that they will use clinical judgement, medical, and nursing knowledge in applying the general principles and recommendations contained within. They are not meant to replace the many available texts on the subject of palliative care.
Some of the management strategies describe the use of drugs outside their licensed indications. They are, however, established and accepted good practice. Please refer to the current BNF for further guidance.
Whilst SPAGG takes every care to compile accurate information , we cannot guarantee its correctness and completeness, and it is subject to change. We do not accept responsibility for any loss, damage or expense resulting from the use of this information.